Breaking News

Curium Acquires Nucleis

Adds manufacturing capacity to meet the growing demand for F-18 tracers and reinforces the reliability of its supply chain.

Author Image

By: Charlie Sternberg

Associate Editor

Curium, a nuclear medicine company, has acquired Nucleis, a specialist in GMP manufacturing and distribution of PET radiopharmaceutical drugs. Founded in 2017 as a spin-off from the University of Liège, Nucleis manufactures and distributes FDG in the Benelux region and offers CDMO services to third-party nuclear medicine players to produce innovative tracers. This acquisition marks a milestone in Curium’s strategic growth in the PET segment, reinforcing its commitment to nuclear medicine i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters